HOME | CONTACT US | LOGIN | REGISTER
 
Print
Email to a Friend

Curriculum Vitae

NAME:

Michael J. Dattoli, M.D.
Dattoli Cancer Center & Brachytherapy Research Institute
2803 Fruitville Road 
Sarasota, Florida 34237

TELEPHONE:

(941) 957-1221 (office)

CITIZENSHIP:

United States

EDUCATION:

Medical Doctorate
Mount Sinai School of Medicine
New York, New York
1985

Bachelor of Arts and Science
Vassar College
Poughkeepsie, New York
1980

POSTDOCTORAL TRAINING:

Special Fellow in Brachytherapy
Memorial Sloan-Kettering Cancer Center 
and New York Hospital - Cornell Medical Center
New York, New York
1989-1990

Radiation Oncology 
New York University Medical Center/Bellevue Hospital Center
New York, New York
1986-1989

Internal Medicine
Westchester County Medical Center and Affiliates
New York, New York
1985-1986

FACULTY APPOINTMENTS:

  • Associate Professor, Memorial Sloan-Kettering Cancer Center (1990 - 91)
  • Member, University of Cincinnati, Endo-Surgery Institute. (1990 - present)

OTHER SPECIALTY TRAINING:

External and Interstitial Hyperthermia
Memorial Sloan-Kettering Cancer Center New York, New York

BOARD CERTIFICATION:

Radiation Oncology, American College of Radiology

LICENSES:

Florida # ME0058562
California # G06985
New York # 182498

AWARDS:

  • Tri-beta Biology Thesis Award, 1980
  • Vassar College Academic Award, 1980

HONORS:

  • Special Honors: Internal Medicine, Obstetrics and Gynecology, Neurology and Radiology, 1983-1984
  • Departmental Honors: Biology, 1980
  • General Honors for Academic Excellence, 1980
  • Phi Beta Kappa, 1980
  • Summa Cum Laude, 1980
  • Highest Grade Point Average, (Valedictorian) Vassar, Class of 1980
  • Dean’s List Honors, 1976-1980
  • Alpha Kappa Psi, Man of the Year; 2008
  • Leading Physicians of the World - top Brachytherapy Oncologist of the World; 2011

SCHOLARSHIPS AND GRANTS:

  • Mount Sinai School of Medicine Scholarship, 1981-1985
  • National Institutes of Health Summer Fellowship Grant, Albert Einstein College of Medicine, 1983
  • National Institutes of Health Summer Fellowship Grant, Albert Einstein College of Medicine, 1981
  • Vassar College Scholarship, 1976-1980

INVESTIGATIVE APPOINTMENTS:

  • Principal Investigator, COMPARE Registry, Sanofi-Synthelabo
  • Principal Investigator, A Phase III, Randomized, Double-Blind, Placebo- Controlled Study of the Safety and Efficacy of 10 mg Astrasenten in Men with Non-Metastatic Hormone Refractory Prostate Cancer, Abbott Oncology (MOO-244)
  • Principal Investigator, Pd-103 seed implant and single daily dosing of Uroxatral versus twice daily dosing of Flomax – A 3-month retrospective efficacy analysis.
  • Sanofi-Aventis Medical Advisory Board, Brachytherapy and Radiation Oncology, Prostate Cancer Research Institute, Los Angeles, CA
  • Medical Advisory Board PAACT (Patient Advocates for Advanced Cancer Treatments) Grand Rapids, MI
  • Principal Investigator, Endovascular Brachytherapy. Theragenics and Johnson and Johnson
  • Principal Investigator, Efficacy of Home Enteral Nutrition Support in Malnourished Patients Receiving Radiation Therapy Involving the Alimentary Tract: An Outcome Study.
  • Multicenter research protocol, IV Onyx-Harvard Research Foundation.

GOVERMENT APPOINTMENTS:

  • Member, Directors, Prostate Cancer Task Force, Tallahassee,FL.
  • Consultant, Washington Oncology Roundtable Advisory Committee

COMMITTEES:

  • Member, Medical Board, National Kidney Registry, 2007
  • Member, Board of Directors, American Brachytherapy Society, Chairman, America Brachytherapy Society Membership Committee 1996-2002.
  • Member, Clinical Research Committee, American Brachytherapy Society Cancer Committee, New York University/Bellevue Hospital, 1987-1989
  • Academic Council, Mount Sinai School of Medicine, 1982-1985

REVIEW BOARDS:

  • Editorial Review Board, Journal of Brachytherapy, 2008-present
  • Editorial Review Board, Journal of Urology, 2009-present
  • Editorial Review Board, Journal of Radiotherapy and Oncology, 2009-   present

PROFESSIONAL SOCIETIES:

  • American College of Radiation Oncology
  • American Society of Therapeutic Radiology and Oncology
  • American Brachytherapy Society
  • Chinese Kenpo Association of America (Medical Officer)

TEXTBOOKS:

  • Prostate Brachytherapy Made Complicated, Dattoli, M, and Wallner, K.,  Blasko, J.:  Third Edition, Smart Medicine Press, 2008
  • Prostate Brachytherapy Made Complicated, Dattoli, M, and Wallner, K.,    Blasko, J.:  Second Edition, Smart Medicine Press, 2001
  • Prostate Brachytherapy Made Complicated, Dattoli, M, and Wallner, K.,  Blasko, J.:  Smart Medicine Press, 1997
  • Basic and Advanced Prostate Brachytherapy, Dattoli, Dicker, et al.; Palladium Brachytherapy: Rationale, Design and Evaluation ; Martin Dunitz and Parthenon Press, 2002 

 

PATIENT GUIDE BOOKS:

  • The Dattoli Challenge: Evaluating Your Prostate Cancer Treatment Options, Dattoli, M, Cash, J, 2011
  • Hormonal Therapy: Will it Benefite Me? (Revised); Dattoli, M, Cash, J, 2010
  • Color-Flow Doppler & Advanced Imaging for Prostate Cancer, Dattoli, M, Cash, J, 2010
  • The Dattoli Blue Ribbon Prostate Cancer Solution:How to Survive and Thrive without Surgery; Dattoli, M, Cash, Jennifer:  Dattoli Cancer Foundation 2009
  • IMRT with DART and Brachytherapy, Dattoli, M, Cash, J 2009
  • Intrepreting Your PSA (Revised), Dattoli, M, Cash, J, 2009
  • Prostate Biopsy:When, Why and What to Expect, Dattoli, J, Cash, J, Fay, J, 2008
  • Brachytherapy and IMRT, Dattoli, M., Cash, J, Kaltenbach, D 2005
  • Hormonal Therapy: Will it Benefit Me?, Dattoli, M, Cash, J, Kaltenbach, D 2005
  • Recurrence: What Do I Do Now?, Dattoli, M, Cash, J, Kaltenbach, D, 2005
  • Interpreting Your PSA, Dattoli, M, Cash, J, Kaltenbach, D, 2005
  • Dosimetry and Prostate Cancer: Precision Design for IMRT and Brachytherapy, Dattoli, M, Cash, J, Kaltenbach, D 2005-2010
  • Surviving Prostate Cancer Without Surgery:The New Gold Standard Treatment that Can Save Your Life and Lifestyle. Dattoli, M, Cash, J and Kaltenbach, D  Seneca House Press 2004
  • Palladium Brachytherapy: Rationale, Design and Evaluation,  Reprint excerpted from Basic and Advanced Prostate Brachytherapy, Dattoli Cancer Foundation, 2004

PATIENT INFORMATION PUBLICATIONS:

RELEVANT PUBLICATIONS:

  • Dattoli, M, Wallner, K, True, L, Bostwick, D, Cash, J & Sorace, R, Long-term Outcomes for Patients with Prostate Cancer having Intermediate and High-risk Disease, treated with Brachytherapy and Supplemental External Beam Radiotherapy.  Journal of Oncology, Vol 2010, Article ID 471375, 6 pages
  • Cash, J, Fay, J & Dattoli, M Combined Modality Treatment for Prostate Cancer with DART using 4D IG IMRT and Brachytherapy.  Journal of Radiology Nursing, 28 (3) September 2009, pg 87-95
  • Fang, Christine, Dattoli, M.J., Taira, Al, True, L, Sorace, R , Wallner, K,  Prostatic Acid Phosphatase Adversely Impacts Cause-Specific Survival in Patients with Higher Risk Prostate Cancer Treated with Pd-103 Brachytherapy, J. Urology, 71 (1) 2008,  pg 146-150
  • Dattoli, M.J., Wallner, K, Cash, J., Sorace, R.  Long-term Outcomes After Treatment with Brachytherapy and Supplemental Conformal Radiation for Prostate Cancer Patients having Intermediate and High-Risk Features,Cancer, Vol 110, No 3, pg 551-555
  • Dattoli, M.J., Wallner, K, True, L.,Cash, J., Sorace, R.  Long-term  Prostate Cancer Control Using Pd-103 Brachytherapy and Beam Radiotherapy in Patients with a High Likelihood of Extracapsular Cancer Extension, Urology, Vol 69 (2), Feb 2007 pg 334-337
  • Wallner, K, Merrick, G, et al, Reviving the Acid Phospatase Test for Prostate Cancer, Oncology, Vol 21,No 8, July 2007
  • Dattoli, M.J., Wallner, K, True, L.,Cash, J., Sorace, R. Long-term outcomes following EBRT + Pd-103 for higher risk prostatic carcinoma: influence of prostatic acid phosphates. Cancer, Vol 97, No 4,  pg 979-983  February, 2003. 
  • Dattoli, M.J., Wallner, K., Sorace, R. Planned Extracapsular Seed     Placement Using Palladium-103 For Prostate Brachytherapy.     International Journal of Brachytherapy. 16: 35-43, April 2000.
  • Dattoli, M.J., Wallner, K., True, L. Prognostic Role of Serum Prostatic Acid Phosphatase For Pd-103 Based Radiation For Prostatic Carcinoma. International J of Radiation-Oncology Biology and Physics 45: 1999.
  • Dattoli, M.J., Wallner, K. Disease-Free Survival After External Beam Irradiation and Palladium-103 Brachytherapy Boost for High-Risk Prostatic Carcinoma. Int Journal of Brachytherapy 13:1-7, 1998.
  • Wallner, K , Dattoli, M.J. Low Risk of Urinary Incontinence Following Prostate Brachytherapy in Patients with a Prior TURP. International Journal of Radiation Oncology , Biology and Physics 37:565-569,1997.
  • Dattoli, M.J. “A Reply From Dr. Dattoli regarding High Risk Prostate     Cancer Treated With Palladium-103” Int J Rad Onc Bio & Phy, 39:    755-756, 1997.
  • Dattoli, M.J., Wallner, K. An Improved Method of Anchoring the 
    Prostate During Interstitial Brachytherapy. Int J Rad Onc Bio & Phy , 38: 341-342, 1997.
  • Cash, J.C., Dattoli, M.J. Management of the Patients Receiving Transperineal Pd-103 Implant. Oncology Nursing Forum 24 (8): 1361-1367, 1997.
  • Nag, S., Baird, M., Blasko, J., Dattoli, M.J. American Brachytherapy Society (ABS) Consensus Guidelines for Permanent Brachytherapy of Prostate Cancer. Proceeding Amer Brachytherapy Society, May 1997.
  • Wallner, K., Dattoli, M.J. Advances in Radiation Therapy for Prostate Cancer; Seed Implantation Therapy. Clinical Courier. 14 (5)L: March 1996
  • Dattoli, M.J., External Beam Irradiation Combined with Palladium-103 Brachytherapy for High-Risk, Localized Prostatic Carcinoma. Int J Rad Onc Bio & Phy 35: 875-879, 1996
  • Dattoli, M.J.,  Lautersztain, J., Mechanick, J. Nutritional Support in Cancer Patients Undergoing Aggressive Radiation Treatments. Nutrition and Clinical Practice 11:53-58, 1996.
  • Armstrong, J.G, Dattoli, M.J., Minsky, B.D., Harrison, L.B., and Fortner, J. The Use of a Prosthetic Tissue Expander to Displace Bowel from a Brachytherapy Implant Site. Int J Rad Onc Bio & Phys 19: 1521-1524, 1992.
  • Dattoli, M.J., Newall, J. Radiation Therapy for Intracranial Germinoma: The Case for Limited Volume Treatment. Int J Rad Onc Bio & Phy :19: 429-431, 1990.
  • Dattoli, M.J., Gretz, H.F., Lerch, I.A., Demopoulos, R. I., Fried, P.R. Multifactorial Analysis of Prognostic Factors in Patients with Stage lB Carcinoma of the Cervix: Age as a Major Determinant. Int J Rad Onc Bio & Phy 17:41-48, 1989.

ABSTRACTS:

  • Bravo, S.M., Dattoli, M.J., Myers, C.E., et al; Ferumoxytol: Potential as Lymphatic Contrast Agent. Submitted to RSNA November 2011.
  • Bravo, S.M., Dattoli, M.J., Myers, C.E., et al; Potential for Feraheme as Lymphatic Contrast Imagine Agent. Submitted to RSNA November 2011.
  • Bravo, S.M., Dattoli, M.J., Myers, C.E., et al; Safety of Ferumoxytol (Feraheme) in Patients with Prostate Carcinoma. Submitted to RSNA November 2011.
  • Bravo, S.M., Dattoli, M.J., Myers, C.E., et al; Ferumoxytol as Lymph Node Contrast Agent in Patients with Metastic Prostate Carcinoma: Rad-Path Correlation. Submitted to RSNA November 2011.
  • Dattoli, M.J., Wallner, K; True, L.; Cash, J.; Sorace, R.A.; Long-term outcomes (16 years) for patients with prostate cancer having intermediate and high-risk disease, treated with brachytherapy and supplemental conformal radiation. 09-AB-20158-ASCOGU Genitourinary Cancer Symposium; Orlando, Florida; February 2009.
  • Dattoli, M.J., Wallner, K; True, L.; Cash, J.; Sorace, R.A.; Long-term 13-year actuarial prostate cancer control with Pd-103 brachytherapy and beam radiation in patients with a high likelihood of extracapsular cancer extension. Int J Rad Onc Bio & Physics, Vol 63, Number 2, 2115, 2005.
  • Dattoli, M.J., Sorace, R., Cash, J., Wallner, K.  Biochemical Failure    Rates Following Combination External Beam Radiation and Palladium-   103 Boost for Clinically Localized High Risk Prostate Cancer: 10 Year    Results: Int J Rad Onc Bio & Phy 54; pg 38, 2002. 
  • Sorace, R., Dattoli, M.J., Low Dose (1000cGy) External Beam Radiation Followed Immediately by Pd-103 Brachytherapy For Patients Having Prostate Cancer and a Single High Risk Feature - Abstract RSNA 2003.
  • Dattoli, M.J., Wallner, K, Palladium 103 Brachytherapy for Clinical    T1/T2 Prostate Cancinoma. Int J. Rad Onc Bio & Phy Proceedings 39:    1011, 1997.
  • Dattoli, M.J., Cash, J.C., Ross, R., Koval, J.M., Sorace, R.A.     Neoadjuvant Hormone Therapy and Palladium-103 Brachytherapy for    Locally Recurrent Prostate Cancer. Proc Amer Soc Clin Onc 1118,    1997. 
  • Dattoli, M.J. Conformal Brachytherapy Boost to External Beam Irradiation for Clinically Localized High Risk Prostate Cancer. Proceedings of the American Society of Therapeutic Radiology, Biology and Physics, October, 1995.
  • Wasserman, S.G., Dattoli, M.J. CT Based Post-Implant Analysis of pre-planned Prostate Implants. Annual Meeting of American Brachytherapy Society , Arizona, December 1995.
  • Dattoli, M.J. Update of Patients Treated with Palladium-103 for Localized Prostate Cancer: The Tampa Experience. Proceedings of the American Brachytherapy Society. 3-23, pg. 39, December, 1994.
  • Dattoli, M.J. Prostatic Brachytherapy with Palladium-103 for Localized prostate Cancer. Report of PSA Response and Toxicity, Radiological Society of North America. 639:230, November 1994.
  • Dattoli, M.J. Prostatic Brachytherapy Using Palladium -103 for Localized Prostate Cancer. Report of Results and Toxicity. Proceedings of the American Society of Clinical Oncology. 800:1994.
  • Dattoli, M.J. Ultrasound Guided Palladium-103 Implants for Treatment of Localized Prostate Cancer: A Preliminary Report. Proceedings of the American Urological Association, 1994.
  • Dattoli, M.J. Transperineal Ultrasound Guided Palladium-103 Implantation for Treatment of Localized Prostate Cancer: Preliminary Report of Toxicity and Outcome as Measured  by Decline of PSA. Annual Meeting American Endocurietherapy Society, 1993. 
  • Lodin, K., Dattoli, M.J Milcu, M.., Newall, J. Radiation Therapy for Adult Spinal Cord Ependymomas: The Case for Limited Volume Treatment. Radiological Society of North America, 1989.
  • Dattoli, M.J, Gretz, H.F., Lerch, I.A., Demopoulos, R.I. Fried, P.R. Cervical Cancer in the Young. ASTRO Abstract. Int J Rad Onc, Bio & Phys 15: 139-140, 1988.

ORAL PRESENTATIONS:

  • “Radiation Therapy for Prostate Cancer Update”  Mount Sinai Medical Center, New York, NY, April 2010
  • “Trends in Radiation Therapy for Prostate Cancer – It’s Evolutionary; It’s Revolutionary”  3rd Annual W.B. Ingalls Memorial Prostate Health and Cancer Seminar; Jupiter, FL, March 2010
  • “Prostate Cancer Recurrence – Detecting and Addressing Using Advanced Technologies” Man-to-Man Regional Conference; Sarasota, FL, January 2009
  • “Prostate Brachytherapy: Pre-, Intra-Op and Post-Op Planning and Dosimetry” Annual Multidisciplinary Cancer Seminar, University of Florida - Shands Hospital, Gainesville, Florida; July 2007
  • Commencement Address and Discussion of “Advances in Prostate Brachytherapy, Staging and Treatment,” Johns Hopkins Hospital, Panama City, Republic of Panama; July 2007
  • “MRI, CFD and other Novel Methods for PCa Staging and Treatment” and “Advances in Radiation Therapy” International Conference on Prostate Cancer, Reston, VA, October 2006
  • “Long-term Outcomes (13 year actuarial) After Treatment with Brachytherapy and 3D-CRT for Patients with High-risk Prostate Cancer,” 2006 Prostate Cancer Symposium: A Multidisciplinary Approach, San Francisco. February 2006.
  • “Prostate Cancer and Radiation Methods using 4D IG-IMRT and Brachytherapy: The State of the Art,” Annual Central American Cancer Symposium, Republic of Panama, December 2005.
  • “Advances in Radiation Therapy:  Brachytherapy, Conventional EBRT to 3D-CRT to IMRT to 4D IG-IMRT and Beyond” Kingston Prostate Cancer Forum, Kingston, NY October 2005.
  • “Advances in Radiation Therapy” National Conference on Prostate Cancer, Washington, DC June 2005.
  • “Advances in Prostate Cancer Brachytherapy,” Annual Central American Cancer Symposium, Republic of Panama, December 2004.
  • “Implant Alone VS. Combination Radiation Therapy for Localized Prostate Cancer”  Shoot-out at Stone Mountain, Stone Mountain, GA.,
    March 19-20, 2004.
  • “Alpha-blockers as Contemporary Management of Benign Prostatic Hyperplagic”  Consensus Meeting Amongst Thought Leaders; Orlando, FL, February 6-8, 2004.
  • “Brachytherapy and IMRT” and “Radiation for Salvage” National Conference on Prostate Cancer – 2003” Burbank, California 
    September 5-7, 2003.
  • “Biochemical Failure Rates Following Combination External Beam Radiation and Palladium-103 Boost for Clinically Localized High Risk Prostate Cancer: 10 Year Results” Annual ASTRO Meeting, New Orleans, October 11-15, 2002.
  • “Prostate Cancer: Present, Past and Future” Kingston Prostate Cancer    Forum - Honorary Guest Speaker; Kingston, NY October 15, 2001. 
  • “Advances in Brachytherapy”. National Conference on Prostate Cancer    2000, Prostate Cancer Research Institute, Long Beach, California.     October 13-15, 2000.
  • “Palladium-103 Update - The Tampa Experience”. Annual ASTRO meeting San Antonio, Texas. November 1-2, 1999.
  • “PAP, the PSA and Prostate Cancer.” American Society of Clinical Pathologist Annual Meeting, Dallas, Texas. September 1998
  • “Prostate Cancer and Transperineal Brachytherapy: The State of the Art.” Ninth Annual Symposium: Pacific Northwest Cancer Institute, Seattle, Washington. June12-13, 1998.
  • “Planned Extra-Capsular Seed Placement for Prostate Brachytherapy.” American Brachytherapy Society Annual Meeting, Albuquerque, New Mexico. May 30-31, 1998.
  • First Symposium Internacional - “Advances in Prostate Cancer.” Sao Paolo, Brazil. November 28-December 2, 1997.
  • “Pd-103 Brachytherapy for Clinical T1/T2 Prostate Carcinoma” 39th Annual ASTRO Meeting. Orlando, Florida. October 19-22, 1997.
  • New Jersey Prostate Cancer Forum. “Prostate Cancer Today and Tomorrow.” Morristown, New Jersey. September 27, 1997.
  • Florida Prostate Cancer Forum. “What Every Man and His Family Needs To Know.” Tampa, Florida. September 13, 1997.
  • “Options for Prostate Cancer.” Florida Academy of Family Physicians-Summer Break Away. Orlando, Florida. July 10-13, 1997.
  • “University Community Hospital Experience and Results.” Eighth Annual Symposium - Transperineal Brachytherapy for Early Stage 
  • Prostate Cancer: The State of the Art. Seattle, Washington. June 12-13, 1997.
  • “Neoadjuvant Hormone Therapy and Palladium-103 Brachytherapy as Salvage for Locally Recurrent Prostate Cancer.” American Society of Clinical Oncology Annual Meeting. Denver, Colorado May 17-20, 1997.
  • “Pd-103 Brachytherapy for Localized Prostate Cancer: The Tampa     Experience.” Prostate Brachytherapy and New Therapeutic Strategies in the Management of Early Stage and Locally Advanced Prostate Cancer. Mount Sinai Medical Center, New York City . March 6-7, 1997.
  • “Brachytherapy: Intraprostatic Seeds Using Pd-103.” Southwest Regional Cancer Conference: Fort Myers, Florida. October 1996.
  • “Prostate Brachytherapy”. New York Prostate Cancer Forum. Kingston, New York. September 1996.
  • “Brachytherapy for Treatment of Prostate Cancer.” Latin American Medical Society. Clearwater, Florida. August 1996.
  • “Pd-103 Brachytherapy for Localized Prostate Cancer: The Tampa Experience.” Seventh Annual Symposium-Prostate Transperineal Brachytherapy: The State of the Art. Seattle, Washington, June, 1996.
  • “Nutrition Support in Patients Undergoing Aggressive Radiation Treatment.” Annual Meeting of American Society for Parenteral and Enteral Nutrition, Washington, D.C. January 1996.
  • “Conformal Brachytherapy Boost to External Beam Irradiation for Clinically Localized High Risk Prostate Cancer.” Annual Meeting of  the American Society of Therapeutic Radiology, Biology and Physics, Miami,  Florida. October 1995.
  • “Update of Patients Treated with Palladium-103 for Localized Prostate Cancer: The Tampa Experience.” Annual Meeting American Brachytherapy Society. December 1994.
  • “Prostatic Brachytherapy with Palladium-103 for Localized Prostate Cancer: Report of PSA Response and Toxicity.” Annual Meeting,
    Radiologic Society of North America, Chicago, Illinois. November 1994
  • “Ultrasound Guided Palladium-103 Radioactive Implants for the Treatment of Prostate Cancer.” Tampa Bay Annual Oncology Update: Cancer of the Prostate. Tampa, Florida. October 1994. 
  • “Transperineal Ultrasound and Fluoroscopic Guided Palladium-103 Implants for the Treatment of Prostate Cancer.” International Meeting 
    of the American Urological Association, London, England. October 1994.
  • “Transperineal Palladium-103 Implants for Localized Prostate Cancer.” Annual Meeting of American Endocurietherapy Society, “Radiation Therapy and Breast Cancer Conservation.” Annual Oncology Update: 
  • Breast Cancer – State of the Art Annual Symposium, Tampa, Florida. September 1993.
  • “High Dose Rate Brachytherapy: Clinical Applications.” Palm Beach Cancer Conference, Good Samaritan Medical Center, Palm Beach, Florida. October 1992.
  • “Radiation Therapy/High Dose Rate Brachytherapy.” Annual Oncology Update: Gynecological Cancer, Tampa, Florida. September 1992.
  • “Radiation Therapy for Intracranial Germinoma: The Case for Limited Volume Treatment.” Annual Meeting of the American Society of Therapeutic Radiologists, San Francisco, California. October 1989.
  • “Multifactorial Analysis of Prognostic Factors in Patients with Stage lB Carcinoma of the Cervix: Age as a Major Determinant.” Annual Meeting of the American Society of Therapeutic Radiologists, New Orleans, Louisiana. October 1988.

HOSPITAL AFFILIATIONS:

  • Sarasota Memorial Hospital, FL – active staff
  • H. Lee Moffitt Cancer Center, Tampa, FL – consulting

Ongoing Collaborative Study Groups:

  • University of Washington, Seattle
  • University of California, San Francisco
  • University of Nijmegan, The Netherlands

Dattoli Cancer Center

2803 Fruitville Road : Sarasota, FL 34237
1-877-DATTOLI (328-8654)
941.957.1221 : 941.957.0038 (fax)